Are there the specific prognostic factors for triplenegative subtype of early breast cancers (pT1-2N0M0)?

You, Ji Young; Lee, Hye-yoon; Woo, S. I.; Park, Kyong Hwa; Lee, Eun-Sook; Bae, Jeoung Won

doi:10.14216/kjco.11014

Cited by 2 publications

(1 citation statement)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These findings are consistent with previous reports from other ethnic groups. [16][17][18][19][20][21][22] In our series, lymphovascular and perineural invasion were found to be significantly higher among patients with TNBC who showed recurrence. Previously, lymphovascular invasion was shown to be associated with increased risk of recurrence in patients who either had breast conservation therapy or mastectomy.…”

Section: Discussionmentioning

confidence: 83%

Determinants of Prognosis in Triple-Negative Breast Cancer: Report from a Large Breast Cancer Registry

et al. 2021

View full text Add to dashboard Cite

Background: The outcome of patients with triple-negative breast cancer (TNBC) is highly dependent on demographic factors and ethnicity. We aimed to evaluate the clinicopathological determinants of prognosis among women with TNBC using data from one of the largest breast cancer (BC) registries. Methods: A total of 6145 patients with BC from our referral center were evaluated from 1995 to 2018, among whom 523 had TNBC. The baseline, menstrual and reproductive, treatment and pathology related characteristics were evaluated. Results: Among TNBC patients, the rate of stage 3 and 4 BC (29.9% vs. 14.4% and 7.8% vs. 0% for stage 3 and 4, respectively; P < 0.001), invasive ductal carcinoma (90.7% vs. 75.6%; P = 0.004), nodal involvement (46.7% vs. 33.4%; P = 0.026), mastectomy (57.3% vs. 37.8%; P = 0.001) and axillary node dissection (76.7% vs. 59.8%; P = 0.019) was significantly higher in the group that developed recurrence. Disease-free-survival was 80.6% (157.76 ± 9.48 months) and overall-survival was 90.1% (182.73 ± 3.28 months). For death, stage 3 BC (compared to stages 0 and 1 as base) showed a higher risk of earlier death (adjusted HR: 4.191, 95% CI = 1.392-12.621; P = 0.011). For recurrence, stage 3 BC (adjusted HR: 1.044, 95% CI = 1.209-6.673; P = 0.017) (compared to stages 0 and 1 as base) showed significantly higher risk for developing earlier recurrence. Moreover, those who had invasive ductal carcinoma (compared to other types of BCs) had a higher risk for developing earlier recurrence (adjusted HR: 3.307, 95% CI = 1.191-0.724; P = 0.012). Conclusion: BC stage plays a significant role in both earlier recurrence and earlier mortality among patients with TNBC.

show abstract